Levomequitazine

Levomequitazine (Compound V0114) ((S) -Mequitazine), the levorotatory enantiomer of Mequitazine (HY-B2168), is an orally active, inverse H4 receptor agonist (IC50s: 94 nM (hM2), 17 nM (hM3) ) . Levomequitazine strongly binds to human histamine H4 receptor. Levomequitazine antagonizes the activating action induced by histamine on H4 receptor. Levomequitazine induces a powerful and statistically significant anti-inflammatory effect. Levomequitazine can be used for research on inflammatory diseases[1].

Product Specifications

CAS Number

[88598-74-7]

Product Name Alternative

(S) -Mequitazine

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Drug Isomer; Histamine Receptor

Related Pathways

GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling; Others

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Smiles

N1(C2=CC=CC=C2SC3=CC=CC=C31)C[C@H]4C5CCN(CC5)C4

Molecular Formula

C20H22N2S

Molecular Weight

322.47

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P362+P364-P405-P501

References & Citations

[1]Thierry Clerc, et al. Mequitazine for treating or preventing pathologies involving histamine h4 receptors. WO2009071625A1. WIPO (PCT) . 2008-12-04.